Covid Statement


At Daiichi Sankyo, our top priority is to help protect the wellbeing and safety of our entire community -- our patients, the healthcare providers who treat them, our employees and our partners.  As such, we have taken measures to contribute to the overall effort to limit the spread of the virus that causes COVID-19.

All Daiichi Sankyo, Inc. employees and contractors who work in our 211 Mt. Airy Road building in Basking Ridge, NJ began working from home, until further notice, on Monday, March 16, 2020.  That same day, all field-based U.S. Business Division employees ceased all live, face-to-face interactions with customers, healthcare providers, payers, and other business associates.

The policies above are in addition to travel restrictions we had already put into place for our associates over the previous several weeks, to support the global effort to limit exposure to the virus that causes COVID-19. 

U.S. Product Supply:  We know the diseases and conditions that are managed with our medicines will not wait for the COVID-19 situation to resolve.  Please be aware that Daiichi Sankyo, Inc. does not have any shortage of its medicines.  Our Supply Chain team is monitoring the evolving situation very carefully to maintain supply and delivery of these medicines to HCPs and their patients.

Approved Products in the U.S.:  As patients and providers still need access to their medications and the information that allows them to use our products safely and effectively, we are able to facilitate communications with our key stakeholders via technology that allows us to communicate remotely.

Though our team members are working remotely, our Representatives, Medical Science Liaisons, and our entire organization are available to support you.  Our contact center is always available for healthcare providers and patients with questions or concerns about our products: 877-437-7763.

Clinical Trials:  We also acknowledge the fact that local clinical resources are being reallocated to meet the needs of the broader community during this time. Daiichi Sankyo is partnering with our clinical trial investigators to support their ability to meet trial protocol and ethics requirements - in behalf of all of our patients during this unprecedented public health crisis.

This support is based on the most recent guidance documents issued by several global health authorities, such as the U.S. Food and Drug Administration, Japan’s Pharmaceuticals and Medical Devices Agency and the European Medicines Agency, which specifically address the topic of how to conduct clinical trials while managing the risks of COVD-19.  We recognize this is a rapidly evolving situation and we will continue to adapt and provide timely updated guidance related to Daiichi Sankyo clinical research.

Thank you for your cooperation as we all navigate this together.